Start your Journal

Neoplasia Research welcomes scholars, institutions, conference organizers and scientific societies to propose and launch new scientific journals under our umbrella.

A committed and experienced Editor-in-Chief is an obligatory requirement to lead the venture. Potential project and proposal management skills are the basic requirements. The essentials for launching a journal are time and professional dedication.

In case you intend to start a new journal, do let us know by sending your proposal. We'll meticulously consider your idea of journal and give you the feedback about offering our platform to you within a week.

Your proposal should include a motivational letter to start a new journal together with:

  1. Your CV with a list of publications and editorial experience
  2. Completed new journal proposal form (Click to download)

Proposals should be sent to at

If the proposal is accepted, the proposer along with the publisher will appoint a suitable Editor-in-Chief from the relevant field. His/ her first responsibility will be to obtain the commitment of the members of the Editorial Board. The Editor-in-Chief will take responsibility for the published content and will encourage submissions from the best and brightest authors in the field.

As your publisher, Neoplasia Research will provide your journal with an ISSN number and will take care of all administrative tasks during the launching period. Our professional staff and an advanced Manuscript Tracking System for submitting and reviewing articles will be at your disposal. We will provide online visibility by creating the web pages of the journal as part of the website.

Neoplasia Research will design the journal, provide a team of technical editors and finalize the content for publication. Our experienced team of scientific publishing professionals will work on getting the journal indexed in the most important and relevant scientific databases.

The journal will follow the Open Access model established with mutual understanding of the Editor-in-Chief and Neoplasia Research.

For any further questions please contact at